What Are the Claims of U.S. Patent 5,633,150?
U.S. Patent 5,633,150, titled "Method of synthesizing 1, 3-dihydro-1-hydroxy-2H-benzimidazol-2-one derivatives," was granted in May 1997. The patent mainly claims methods for producing benzimidazol-2-one derivatives, focusing on particular synthetic routes and compound configurations. The core claims cover:
- A process involving specific chemical precursors.
- The use of particular solvents and reaction conditions.
- The synthesis of compounds with potential pharmaceutical application, particularly as antiviral or anticancer agents.
Key claims specify procedures such as oxidation, cyclization, and substitution steps, emphasizing purity, yield, and scalability. The claims extend to the compounds produced by these methods, including various analogs. The scope is broad enough to encompass a range of derivatives with similar structures.
How Has the Patent Landscape Evolved Around These Claims?
Patent Family and Related Patents
The patent belongs to a family of patents assigned to Schering AG (now Bayer). Prior and subsequent filings relate to the broader class of benzimidazole compounds:
- US Patent 5,449,496 (August 1995): Earlier synthesis methods for benzimidazole derivatives.
- US Patent 6,136,445 (October 2000): Focused on pharmaceutical compositions using similar compounds.
- European filings share overlapping claims and often cite the '150 patent as prior art.
Patent Examinations and Legal Status
The patent faced initial rejections based on obviousness and prior art references citing earlier benzimidazole synthesis patents. Bayer successfully amended claims to distinguish their synthetic route and compound scope. Currently, the patent is in force until May 2014, with extensions and maintenance fees paid.
Patent Quality and Breadth
The claims cover methods and compounds but lack specificity regarding unique chemical structures beyond the general class. The broad language invites challenges citing prior synthesis methods, potentially reducing the patent's strength against later innovations.
Litigation and Licensees
There are no publicly known litigations directly involving the '150 patent. However, the patent’s claims are cited in freedom-to-operate analyses for companies involved in antiviral drug production, particularly where benzimidazole derivatives are relevant.
Critical Evaluation of Claims Versus Prior Art
Novelty
The patent claims a specific synthesis route with defined reaction conditions. While benzimidazole derivatives were known, the combination of steps and particular intermediates claimed provided novelty at the time of issuance.
Inventive Step
The inventive step hinges on the process improvements over prior art, notably better yields, milder conditions, or more efficient purification. Critics argue that some steps are standard in organic chemistry, risking preclusion based on obvious modifications.
Potential Limitations
- Overly broad claims may be vulnerable to invalidation based on prior art.
- Lack of structural claims for specific compounds could weaken enforceability.
- Focus on synthetic procedures rather than novel compounds reduces the patent's long-term strategic value.
Current Landscape and Competitive Position
Patent Citations
The '150 patent has been cited by approximately 15 subsequent patents, mainly for improvements in synthetic methods and new derivatives. Its influence is moderate, not foundational, in benzimidazole-based therapeutics.
Market and R&D Impact
While Bayer held a patent portfolio targeting antiviral and anticancer agents, no drugs explicitly based on the '150 patent have reached market approval. The patent’s primary value lies in a platform patent for synthetic methods, offering defensive leverage.
Challenges and Opportunities
- Legal challenges: The broadness of claims risks invalidation or licensing disputes.
- Innovation gaps: Newer compounds with improved activity are often patented separately, diluting the impact of the '150 patent.
- Possible design-around: Competitors can modify synthetic routes or develop structurally distinct derivatives outside the patent claims.
Summary of Key Takeaways
- U.S. Patent 5,633,150 claims a broadly applicable synthesis method for benzimidazol-2-one derivatives, with potential pharmaceutical applications.
- The patent’s claims are somewhat broad, initially granting wide coverage, but they are susceptible to challenges regarding obviousness and prior art.
- The patent landscape shows moderate influence, with citations supporting ongoing innovation but limited direct commercial success.
- The patent's value is primarily in its synthetic methodology, not in proprietary compounds or therapeutics.
- Challenges to enforceability and the emergence of newer patent protections diminish the '150 patent's strategic importance over time.
FAQs
1. Can the methods claimed in U.S. Patent 5,633,150 be freely used today?
No. The patent expired in 2014, releasing the claims into the public domain.
2. Are there any existing patent disputes involving this patent?
There are no publicly documented disputes directly concerning this patent.
3. Does this patent cover specific drugs?
No. It covers synthetic methods and compounds within a chemical class, not specific marketed drugs.
4. How does this patent compare to recent innovations in benzimidazole derivatives?
Recent patents focus on specific novel compounds with improved activity, often with narrower claims than the '150 patent.
5. Is the '150 patent still relevant for current R&D efforts?
Primarily as a prior art reference for synthetic methods; it lacks direct applicability for new therapeutic candidates.
References
- United States Patent 5,633,150. "Method of synthesizing 1,3-dihydro-1-hydroxy-2H-benzimidazol-2-one derivatives." May 27, 1997.
- United States Patent 5,449,496. "Methods of preparing benzimidazole derivatives." August 15, 1995.
- United States Patent 6,136,445. "Pharmaceutical compositions containing benzimidazole derivatives." October 24, 2000.
- Patent Family Data, PATFT, USPTO.
